Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Kisunla (donanemab-azbt), Lilly's ...

Kisunla™ (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

Kisunla was initially approved by the FDA in July 2024 based on the TRAILBLAZER-ALZ 2 Phase 3 clinical trial data, which demonstrated the drug slowed cognitive and functional decline in early ...

Neither Kisunla (donanemab, Eli Lilly and Co. Inc.) or Leqembi (lecanemab, Eisai Co. Ltd.), “demonstrate sufficient benefit to justify their high cost, including the cost of administering them,” the ...

Neither Kisunla (donanemab, Eli Lilly & Co. Inc.) or Leqembi (lecanemab, Eisai Co. Ltd.) “demonstrate sufficient benefit to justify their high cost, including the cost of administering them,” the ...

Warnings - Kisunla can cause serious allergic and infusion-related reactions. Do not receive Kisunla if you have serious allergic reactions to donanemab-azbt or any of the ingredients in Kisunla.

Kisunla, an amyloid-targeting therapy, is now the first of its kind registered in Australia. It works by removing amyloid plaques, which are associated with Alzheimer’s disease, from the brain ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling.

Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the brain ...

Drugs can't stop Alzheimer's disease but sometimes, they can slow it down. This was one woman's experience taking the drug Kisunla.